Home Ingredients AvailOm® (Omega-3 Lysine Salt)
Joint Health

AvailOm® (Omega-3 Lysine Salt)

Evidence Level
Limited
5 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

AvailOm® is a dry powder from Evonik in which the omega-3 fatty acids EPA and DHA, taken from fish oil or algae oil, are present as free fatty acids bound to the amino acid L-lysine. The maker states it holds about 50% EPA and DHA by weight and is pressed into small tablets or filled into capsules. In single-dose studies funded or co-authored by Evonik, blood EPA and DHA rose more than after ethyl ester or triglyceride fish oil products taken on an empty stomach; these are blood markers, not health outcomes. In one 8 week Evonik-funded trial in adults over 40 with persistent knee pain, pain ratings fell more than with placebo, while the overall WOMAC score did not differ from placebo. In a 4 week trial of a probiotic combination, the omega-3 index rose less than with fish oil, and inflammation markers did not change.

Studied Dose Single fasting doses of 802 mg (500 mg EPA, 302 mg DHA) and 1,100 mg EPA plus DHA in absorption studies; 4 tablets a day for 8 weeks in a knee trial (mg not reported); 250 mg EPA plus DHA a day with a probiotic for 4 weeks.
Active Compound EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) as free fatty acids paired 1:1 by molecule with L-lysine, about 2:1 fatty acid to lysine by weight, as a powder. Evonik grades: 50 High EPA (at least 30% EPA and 15% DHA, from fish oil), 50 High DHA (fish oil) and 50 High DHA Algae (at least 48% DHA). One paper lists about 11 to 25% other fatty acids.

Benefits

Knee comfort in adults with persistent knee pain

In 120 adults over 40 with persistent knee pain, 4 tablets a day containing AvailOm for 8 weeks lowered pain ratings from 5.3 to 2.3 versus 5.1 to 4.0 on placebo, the primary measure. The overall WOMAC score, also a registered primary outcome, did not differ from placebo for AvailOm alone. One trial, funded by the maker with two maker employees as authors.

Supported by Trial 1

Blood EPA and DHA after a single dose

In two crossover studies (8 women and 21 adults) taken on an empty stomach, plasma EPA and DHA rose more over 12 hours after the lysine salt than after an ethyl ester fish oil, and more than a triglyceride fish oil in the larger one. Plasma levels are a marker of uptake, not a health outcome, and both studies had maker funding or maker authors.

Supported by Trial 3, Trial 2

Omega-3 index over 4 to 8 weeks

In the 8 week knee trial, the omega-3 index, the share of EPA plus DHA in red blood cell membranes, rose 0.68 points more than placebo. In a 4 week trial at 250 mg a day with a probiotic, it rose more than placebo but less than with 300 mg of fish oil (0.12 versus 0.5 points). The omega-3 index is a blood marker.

Supported by Trial 4, Trial 1

Pro-resolving lipid mediators with a probiotic combination

In 72 healthy adults, 4 weeks of capsules combining AvailOm with the probiotic Bacillus megaterium DSM 32963 and selenium raised plasma 18-HEPE plus 5-HEPE about 3.5-fold versus placebo, the primary endpoint, versus about 1.2-fold with 300 mg of fish oil. These are blood markers, and the effect cannot be assigned to AvailOm alone.

Supported by Trial 4, Trial 5

CRP and TNF-alpha in a 4 week trial

In the same 4 week trial, enrolled adults had raised hsCRP or glycation markers at the start, yet hsCRP and TNF-alpha did not change in the probiotic combination, fish oil or placebo groups. Total plasma EPA and DHA also did not differ from placebo at 250 mg a day.

Supported by Trial 4

Mechanism of action

1

Free fatty acids that need no fat-digesting enzyme

In fish oil, EPA and DHA sit in triglycerides or ethyl esters that lipase enzymes must split before uptake. In AvailOm they are free fatty acids paired with lysine; in a lab test the salt fully separated under simulated stomach and gut conditions. Maker-funded authors propose this explains the faster rise in blood levels on an empty stomach.

2

Blood vessel relaxation in mouse arteries, a lab finding

In isolated mouse resistance arteries, AvailOm relaxed the vessels in a dose-dependent way through AMPK and eNOS signaling, and a mix with anthocyanins protected the vessels from oxidized-LDL damage. The authors found the omega-3 ethyl ester part of AvailOm relaxed the vessels as much as the whole product. This was lab work in animal tissue, not a study in people.

3

Raw material for bacterial lipid mediators, lab and combination work

In the lab, the probiotic Bacillus megaterium DSM 32963 turned the free fatty acids of AvailOm into pro-resolving lipid mediators, which it could not do with fish oil triglycerides. In people the combination raised the mediator precursors 18-HEPE and 5-HEPE, a blood marker without a shown health effect.

Clinical trials

1
AvailOm 50 High EPA for 8 Weeks in Adults With Persistent Knee Pain
PubMed

Single-center, randomized, double-blind, four-arm trial: Boswellia, AvailOm 50 High EPA (25% of each film-coated tablet), both, or placebo, 4 tablets a day for 8 weeks; mg of EPA plus DHA per day not reported. Primary variable: knee pain on a visual analog scale; the registration also lists the WOMAC score as primary. Funded by Evonik Operations GmbH, which supplied the products; Evonik employees M. Gómez and M. Schölzel were authors (Pérez-Piñero et al. 2023, Nutrients)

Healthy adults aged 40 to 75 in Spain with persistent knee pain above 3 on a 10 cm scale; 130 randomized, 120 completers analyzed (31 on AvailOm, 30 on placebo).

Pain fell from 5.3 to 2.3 with AvailOm and from 5.1 to 4.0 with placebo (mean difference -1.779, p = 0.003); weekly pain scores also favored AvailOm (p = 0.045). The overall WOMAC score and its pain items did not differ from placebo for AvailOm alone; only the AvailOm plus Boswellia arm beat placebo on WOMAC. Boswellia alone lowered pain ratings by a similar amount (mean difference -1.784). Only completers were analyzed. Timed Up and Go time fell within the AvailOm group. Omega-3 index rose 0.683 points more than placebo (p = 0.009). Adverse events were mild and judged unrelated.

2
AvailOm vs Ethyl Ester and Triglyceride Fish Oil: Single-Dose Crossover
PubMed

Randomized three-way crossover with 14 day washouts; single fasting doses of 1,100 mg EPA plus DHA as AvailOm 50 High EPA (7 capsules), an ethyl ester fish oil (2 capsules) and a triglyceride fish oil (3 capsules). Primary endpoint: plasma EPA plus DHA area under the curve over 12 hours. Funded by Evonik Operations GmbH; R. Bosi was an Evonik employee and V. Gourineni a former Evonik employee (Schön et al. 2024, Food Nutr Res)

21 healthy adults (10 men, 11 women), mean age 41.7, with an omega-3 index of 6.0% or less.

Dose-adjusted plasma EPA plus DHA over 12 hours was 9.33 times the ethyl ester value and 1.57 times the triglyceride value; peak rise and time to peak did not differ significantly from the triglyceride product. 6 of 21 rated AvailOm slightly unpleasant and 1 very unpleasant, the latter citing fishy aftertaste and burping. No health outcome was measured.

3
Lysine Salt of EPA and DHA vs Ethyl Ester: First Human Absorption Study
PubMed

Lab dissolution tests plus an open-label, randomized two-way crossover of single fasting doses: lysine salt (500 mg EPA plus 302 mg DHA) versus an ethyl ester supplement (504 mg EPA plus 378 mg DHA), blood sampled over 48 hours. Evonik Operations GmbH authors L. Headley, R. Bosi and M. Schwarm; funding not stated in the abstract (Manusama et al. 2021, Prostaglandins Leukot Essent Fatty Acids)

8 female volunteers.

The salt fully dissociated in simulated stomach and intestinal fluids. Plasma EPA and DHA area under the curve over 12 hours and peak levels were higher than with the ethyl ester (p < 0.001), with EPA area about 5 times higher. Plasma levels only; no health outcome.

4
AvailOm Plus Bacillus megaterium Probiotic for 4 Weeks: Placebo and Fish Oil Comparison
PubMed

Double-blind, randomized, placebo-controlled parallel trial with an unblinded fish oil arm (300 mg EPA plus DHA a day); test capsules gave 250 mg EPA plus DHA a day as AvailOm lysine salt with Bacillus megaterium DSM 32963 and selenium, coated for colon delivery. Primary endpoint: plasma 18-HEPE plus 5-HEPE. Funded by Evonik Operations GmbH, which made the capsules; Evonik employees B. Speckmann and H. tom Dieck were authors (Speckmann et al. 2024, Nutrients)

72 healthy nonsmoking adults aged 30 to 75 with raised hsCRP or glycation markers and an omega-3 index of 6.5% or less (23 combination, 24 placebo, 25 fish oil).

18-HEPE plus 5-HEPE rose about 3.5-fold with the combination versus no change on placebo. Omega-3 index rose more than placebo (p = 0.0088) but less than with fish oil (0.12 versus 0.5 points); total plasma EPA and DHA did not differ from placebo. hsCRP and TNF-alpha did not change in any group; triglycerides did not differ from placebo (p = 0.10).

5
Omega-3 Lysine Salt and Probiotic Combination: Open-Label Pilot
PubMed

Open-label, single-arm 4 week pilot without a control group; 2 capsules a day supplied 477 mg omega-3 lysine salt with Bacillus megaterium DSM 32963, hyaluronic acid, coenzyme Q10, lecithin, vitamins, zinc and selenium. Funded by Evonik Operations GmbH; Evonik employees B. Speckmann, J. Kleinbölting, S. Pelzer and H. tom Dieck were authors (Speckmann et al. 2022, Nutrients)

19 healthy women aged 35 to 60 with a BMI of 25 to 35 and low fatty fish intake.

Plasma 18-HEPE, 15-HEPE, 5-HEPE, 7-HDHA and 4-HDHA rose from baseline, as did EPA and DHA. With no control group and a multi-ingredient product, the changes cannot be assigned to the omega-3 salt. 17 adverse events in 9 women were judged unrelated; some disliked the capsule size and odor.

Side effects and drug interactions

Common Potential side effects

Fishy aftertaste and burping: after a single fasting dose of 1,100 mg EPA plus DHA as AvailOm (7 capsules), 6 of 21 adults rated it slightly unpleasant and 1 very unpleasant because of fishy aftertaste and burping, compared with 2 slightly unpleasant ratings for a triglyceride fish oil.
In the 8 week knee trial, 21 mild adverse events, mostly constipation, diarrhea and heartburn, were recorded across the groups and judged unrelated to the products; blood tests stayed in the normal range. In a 4 week probiotic combination trial, one person had burping, flatulence and stomach pressure rated as possibly related.
Published AvailOm trials lasted from a single dose to 8 weeks, so longer-term use has not been studied in published trials. A 6 month placebo-controlled trial was registered with no results posted.
Source: Evonik makes the High EPA and High DHA grades from fish oil and the High DHA Algae grade from algae oil, so check the grade if you avoid fish.
Atrial fibrillation: in pooled outcome trials of marine omega-3 (not AvailOm), omega-3 was linked to more atrial fibrillation, more in trials testing above 1 g a day. People with heart rhythm problems should ask their cardiologist before high-dose use.

Important Drug interactions

No drug interaction studies of AvailOm have been published.
Blood thinners and antiplatelet drugs: in a trial of 4 g a day of a prescription EPA drug (not AvailOm), serious bleeding was 2.7% versus 2.1% on placebo (P = 0.06). Ask your doctor before adding omega-3 if you take these medicines.
Prescription omega-3 drugs: ask your prescriber before adding an omega-3 supplement to a prescription EPA or EPA plus DHA product.

More Joint Health Ingredients

Joint Health
Chondroitin
Chondroitin sulfate is a glycosaminoglycan, a long chain of sugar units that forms part of…
Joint Health
Boswellia Serrata
Boswellia serrata, also called Indian frankincense, is a tree whose gum resin is used in s…
Joint Health
NEM® (Natural Eggshell Membrane — ESM Technologies)
NEM® is the branded standardized natural eggshell membrane developed by ESM Technologies (…
Joint Health
Undenatured Type II Collagen
Undenatured Type II Collagen (sometimes abbreviated UC-2 or native Type II collagen) is a…

Frequently asked questions about AvailOm® (Omega-3 Lysine Salt)

What is AvailOm?

AvailOm is an Evonik ingredient in which the omega-3 fatty acids EPA and DHA are present as free fatty acids bound to the amino acid L-lysine, forming a dry powder. Evonik states it contains about 50% EPA and DHA by weight and sells fish oil grades rich in EPA or DHA and an algae oil grade rich in DHA, used in tablets and capsules.

Is AvailOm absorbed better than fish oil?

Evonik claims bioavailability several times that of fish oil softgels. In single-dose studies funded or co-authored by Evonik and taken on an empty stomach, blood EPA and DHA rose more than after ethyl ester or triglyceride fish oil. In a 4 week trial at a low dose with a probiotic, though, the omega-3 index rose less than with fish oil. Blood levels are markers, not health outcomes.

Has AvailOm been studied for joint comfort?

One 8 week trial in 120 adults over 40 with persistent knee pain found larger drops in pain ratings with 4 AvailOm tablets a day than with placebo. The overall WOMAC score did not differ from placebo for AvailOm alone. Evonik funded the trial and two authors worked for the company, and it has not been repeated.

How much EPA and DHA do AvailOm studies use?

Absorption studies used single doses of 802 mg and 1,100 mg of EPA plus DHA, and a 4 week probiotic combination used 250 mg a day. The knee trial used 4 tablets a day but did not report the mg of EPA plus DHA. Check the EPA plus DHA on the label rather than the total powder weight, since about one third of the salt is lysine.

What is AvailOm used for?

AvailOm is researched primarily for Joint Health. In 120 adults over 40 with persistent knee pain, 4 tablets a day containing AvailOm for 8 weeks lowered pain ratings from 5.3 to 2.3 versus 5.1 to 4.0 on placebo, the primary measure.

Is AvailOm safe, and does it have side effects?

Side effects and cautions reported for AvailOm include: Fishy aftertaste and burping: after a single fasting dose of 1,100 mg EPA plus DHA as AvailOm (7 capsules), 6 of 21 adults rated it slightly unpleasant and 1 very unpleasant because of fishy aftertaste and burping, compared with 2 slightly unpleasant ratings for a triglyceride fi… It may also interact with some medications. AvailOm is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does AvailOm interact with any medications?

Possible interactions include: No drug interaction studies of AvailOm have been published. Blood thinners and antiplatelet drugs: in a trial of 4 g a day of a prescription EPA drug (not AvailOm), serious bleeding was 2.7% versus 2.1% on placebo (P = 0.06). If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for AvailOm?

NutraSmarts rates the evidence for AvailOm as Limited (2 out of 5). It is backed by 5 study summaries and 12 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(12 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Schön C, Micka A, Gourineni V, Bosi R. Superior bioavailability of EPA and DHA from a L-lysine salt formulation: a randomized, three-way crossover study. Food Nutr Res. 2024;68. doi: 10.29219/fnr.v68.11028.PubMedUsed to support: Randomized three-way crossover study in 21 healthy adults (10 men, 11 women) with an omega-3 index of 6.0% or less. Single fasting doses of 1,100 mg EPA plus DHA as AvailOm 50 High EPA (7 capsules; 31 to 37% EPA and 15 to 20% DHA), a fish oil ethyl ester product (2 capsules) and a fish oil triglyceride product (3 capsules), 14 day washouts. Dose-adjusted plasma EPA plus DHA over 12 hours (primary endpoint) was 9.33 times the ethyl ester and 1.57 times the triglyceride value; peak rise did not differ significantly from the triglyceride product. 6 of 21 rated AvailOm slightly unpleasant and 1 very unpleasant, the latter citing fishy aftertaste and burping. Funded by Evonik Operations GmbH; one author was an Evonik employee and one a former Evonik employee. The paper describes the salt as EPA- and DHA-rich free fatty acids bound 1:1 to L-lysine, about 2:1 by weight, with at least 50% EPA plus DHA.
  2. Manusama K, Balvers M, Diepeveen-de Bruin M, Headley L, Bosi R, Schwarm M, Witkamp R. In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA. Prostaglandins Leukot Essent Fatty Acids. 2021;164:102232. doi: 10.1016/j.plefa.2020.102232.PubMedUsed to support: Lab part: the lysine salt fully dissociated under simulated stomach and intestinal conditions. Human part: open-label, randomized two-way crossover in 8 women given single fasting doses of the lysine salt (500 mg EPA plus 302 mg DHA) or an ethyl ester supplement (504 mg EPA plus 378 mg DHA). Plasma EPA and DHA area under the curve over 12 hours and peak levels were higher with the salt (p < 0.001), with EPA area about 5 times higher. Three of the seven authors were affiliated with Evonik Operations GmbH; the abstract does not state funding.
  3. Pérez-Piñero S, Muñoz-Carrillo JC, Victoria-Montesinos D, García-Muñoz AM, Andreu-Caravaca L, Gómez M, Schölzel M, García-Guillén AI, López-Román FJ. Efficacy of Boswellia serrata Extract and/or an Omega-3-Based Product for Improving Pain and Function in People Older Than 40 Years with Persistent Knee Pain: A Randomized Double-Blind Controlled Clinical Trial. Nutrients. 2023;15(17):3848. doi: 10.3390/nu15173848.PubMedUsed to support: Single-center, double-blind, four-arm trial in Spain in healthy adults over 40 with persistent knee pain (VAS above 3): Boswellia, AvailOm 50 High EPA (25% of each film-coated tablet, with lecithin), both, or placebo, 4 tablets a day for 8 weeks; the paper does not give mg of EPA plus DHA per day. 130 randomized, 120 completers analyzed. End-of-study pain (VAS, the primary variable) fell from 5.3 to 2.3 with AvailOm versus 5.1 to 4.0 with placebo (mean difference -1.779, p = 0.003). The overall WOMAC score and its pain items improved more than placebo only in the AvailOm plus Boswellia group, not with AvailOm alone. Boswellia alone lowered pain ratings by a similar amount (mean difference -1.784). Only completers were analyzed. Omega-3 index rose more than placebo (0.683 points, p = 0.009). 21 mild adverse events, mostly digestive, were judged unrelated. Funded by Evonik Operations GmbH, which supplied the products; two authors were Evonik employees.
  4. Speckmann B, Wagner T, Jordan PM, Werz O, Wilhelm M, Tom Dieck H, Schön C. Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study. Nutrients. 2024;16(9):1354. doi: 10.3390/nu16091354.PubMedUsed to support: Double-blind, randomized, placebo-controlled 4 week trial in 72 healthy adults aged 30 to 75 with raised hsCRP or AGEs, plus an unblinded fish oil arm (300 mg EPA plus DHA a day). The test capsules combined AvailOm lysine salt (250 mg EPA plus DHA a day), the probiotic Bacillus megaterium DSM 32963 and selenium. The primary endpoint, plasma 18-HEPE plus 5-HEPE, rose about 3.5-fold versus no change on placebo. The omega-3 index rose more than placebo (p = 0.0088) but less than with fish oil (0.12 versus 0.5 points); total plasma EPA and DHA did not differ from placebo; hsCRP and TNF-alpha did not change in any group. Funded by Evonik Operations GmbH, which made the capsules; two authors were Evonik employees.
  5. Speckmann B, Kleinbölting J, Börner F, Jordan PM, Werz O, Pelzer S, Tom Dieck H, Wagner T, Schön C. Synbiotic Compositions of Bacillus megaterium and Polyunsaturated Fatty Acid Salt Enable Self-Sufficient Production of Specialized Pro-Resolving Mediators. Nutrients. 2022;14(11):2265. doi: 10.3390/nu14112265.PubMedUsed to support: Lab part: Bacillus megaterium strains converted AvailOm (described as about 33% L-lysine and 67% omega-3 fatty acids: 30 to 35% EPA, 15 to 20% DHA, 11 to 25% other fatty acids) into pro-resolving lipid mediators. Human part: open-label, single-arm 4 week pilot in 19 healthy women with a BMI of 25 to 35 taking capsules with 477 mg omega-3 lysine salt a day plus the probiotic, hyaluronic acid, coenzyme Q10, vitamins and minerals; plasma HEPEs, HDHAs, EPA and DHA rose from baseline. No control group. Funded by Evonik Operations GmbH; four authors were Evonik employees.
  6. Di Pietro P, Lizio R, Izzo C, Visco V, Damato A, Venturini E, De Lucia M, Galasso G, Migliarino S, Rasile B, Ciccarelli M, Vecchione C, Carrizzo A. A Novel Combination of High-Load Omega-3 Lysine Complex (AvailOm(®)) and Anthocyanins Exerts Beneficial Cardiovascular Effects. Antioxidants (Basel). 2022;11(5):896. doi: 10.3390/antiox11050896.PubMedUsed to support: Lab study in isolated mouse resistance arteries, not people. AvailOm relaxed the vessels in a dose-dependent way through AMPK and eNOS signaling, and AvailOm combined with anthocyanins protected the arteries from oxidized-LDL damage. The omega-3 ethyl ester component relaxed the arteries as much as the whole product. Evonik employee R. Lizio was a co-author and supplied the products.
  7. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021;144(25):1981-1990. doi: 10.1161/CIRCULATIONAHA.121.055654.PubMedUsed to support: Not a study of AvailOm. Pooled 7 cardiovascular outcome trials of marine omega-3 (81,210 people): omega-3 was linked to more atrial fibrillation (hazard ratio 1.25), more in trials testing above 1 g a day (1.49) than at or below 1 g a day (1.12).
  8. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812792.PubMedUsed to support: Not a study of AvailOm: a trial of 4 g a day of icosapent ethyl, a prescription purified EPA drug, in 8,179 statin-treated adults. Serious bleeding was 2.7% versus 2.1% on placebo (P = 0.06), and hospitalization for atrial fibrillation or flutter was 3.1% versus 2.1%. Funded by Amarin Pharma.
  9. Evonik Industries AG. AvailOm®: a platform of omega-3 powders for superior bioavailability, stability and convenience. Evonik (manufacturer web page). 2026;Manufacturer product page (accessed 2026)..SourceUsed to support: Not PubMed-indexed; maker web page read. Evonik describes AvailOm as free-flowing powders, directly compressible into tablets or used in hard capsules, with 50% EPA and DHA as free fatty acids by weight combined with the amino acid lysine. Grades: 50 High EPA (fish oil, at least 30% EPA and 15% DHA), 50 High DHA (fish oil) and 50 High DHA Algae (algae oil, at least 48% DHA). Maker claims include bioavailability more than five times that of liquid omega-3 softgels and oxidation resistance of at least 4 years.
  10. Evonik Industries AG. Evonik launches ground-breaking omega-3 product for dietary supplements (press release). Evonik (press release). 2017;Press release, September 27, 2017 (accessed 2026)..SourceUsed to support: Not PubMed-indexed; maker press release read. Describes AvailOm as an omega-3 lysine powder with at least 45 percent EPA and DHA by weight, pressed into small tablets, with absorption as free fatty acids without enzymatic conversion. The maker states it was cleared for sale in the USA (both NDI and GRAS) and claims three to five times the bioavailability of fish oil capsules.
  11. Universidad Católica San Antonio de Murcia; Evonik Operations GmbH (collaborator). Efficacy of a Dietary Ingredient Combination With Omega-3 for Joint Function (ClinicalTrials.gov registration NCT05279573). ClinicalTrials.gov. 2022;NCT05279573 (accessed 2026)..SourceUsed to support: Not PubMed-indexed; trial registration read through the ClinicalTrials.gov API. Lists two primary outcomes, change in knee pain on a visual analog scale and the WOMAC quality of life score at 8 weeks, with Evonik Operations GmbH as collaborator.
  12. Helse Stavanger HF; Evonik Industries AG (collaborator). Effects of an Omega-3 Fatty Acid-based Supplement on Healthy Ageing (ClinicalTrials.gov registration NCT06150261). ClinicalTrials.gov. 2023;NCT06150261 (accessed 2026)..SourceUsed to support: Not PubMed-indexed; trial registration read through the ClinicalTrials.gov API. Placebo-controlled trial of 5 AvailOm capsules a day for 6 months, started December 2023, last known status recruiting, estimated completion December 2025; no results posted.